Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
294 articles
Go beyond the basics and explore how GLP-1 coordinates insulin release, appetite suppression, and cellular protection — and why these mechanisms matter for long-term metabolic health.
Explore how sirtuins use NAD+ as a molecular switch to regulate aging, DNA repair, and metabolism — and what happens when this system breaks down.
A large prospective cohort study finds long-term exposure to pyrethroid pesticides raises fasting glucose, insulin resistance, and type 2 diabetes risk.
Mayo Clinic review covers every FDA-approved obesity medication plus pipeline drugs, with head-to-head weight loss data and clinical best practices.
Dexcom G7 tops expert picks for metabolic biohacking, but evidence for non-diabetics remains mixed. Here's what the data says.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
Expert reviews compare top CGMs for longevity use, but evidence for healthy adults remains limited. Here's what you need to know.
A Japanese family case reveals how inherited HNF1A and ABCC8 mutations act additively to accelerate early-onset diabetes beyond either variant alone.
A newly identified mitochondrial NAD transporter in fat cells controls whether you develop obesity and insulin resistance as you age.
A newly discovered amygdala–liver neural circuit drives stress hyperglycemia independently of cortisol or adrenaline — and chronic stress breaks it.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
The FDA reportedly approved Eli Lilly's orforglipron, a daily oral GLP-1 receptor agonist for obesity, marking a potential shift from injectable weight-loss drugs.
